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that setting arbitrary benchmarks based on empirical observation of compara-
tive EU countries is incorrect due to wide inconsistencies over pharmaceutical 
distribution.
PHP96
HTA Informed PrIce negoTIATIons: cosT sAvIngs To THe HeAlTH PAyer 
In IrelAnd
McCullagh L.M.1, Tilson L.1, Adams R.1, Barry M.2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2HSE Medicines Management 
Programme, Dublin, Ireland
Objectives: In Ireland, the reimbursement decision process involves the Marketing 
Authorisation Holder (MAH) submitting a Health Technology Assessment (HTA) dos-
sier to the National Centre for Pharmacoeconomics (NCPE). The NCPE evaluates 
this dossier and submits a reimbursement recommendation to the Health Service 
Executive (HSE) (the decision maker). Along with Cost-Effectiveness and Budget 
Impact analyses, the decision maker considers other criteria in determining the 
health benefit of an intervention. Those interventions which are not deemed cost 
effective at a threshold of € 45,000/QALY may proceed to HTA informed HSE-MAH 
price negotiations. The aim of this study was to estimate the potential annual cost 
savings (reduced potential budget impacts) to the HSE as a consequence of HTA 
informed price negotiations. MethOds: All NCPE assessments received over a 2 
year period were reviewed. Interventions were included if initially they had not been 
recommended for reimbursement, but had subsequently been reimbursed after 
HTA informed price negotiations. The potential total annual cost saving to the HSE 
(difference between the original Gross BI (submitted price) and the revised Gross 
BI (negotiated price) was estimated. The respective MAH BI models were used for 
these analyses. Results: Eight interventions fitted the inclusion criteria; all were 
classified as either oncology drugs or drugs for orphan diseases. When all such 
drugs are considered, it is estimated that the cost savings to the HSE, as a result of 
HTA informed price negotiations is over € 19 million per annum. cOnclusiOns: 
In Ireland, HTA informed price negotiations lead to considerable cost savings to 
the Health Payer.
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Objectives: - To assess access to NCD medicine in India using public drug procure-
ment data. MethOds: - State procurement data was used to calculate, total and per 
capita value of procurement towards purchase of essential medicines. ABC analysis 
was performed to identify priority medicines that together account for 80% of total 
expenditure (Category A items). The proportion of NCD medicines among category A 
items was then estimated. Finally, the efficiency of the system was captured through 
comparative price analysis of procurement price to International Reference Price 
(IRP). Results: - Out of the 91 NCD medicines on WHO list of essential medicine, 
states were procuring 40 to 87 NCD medicines. In addition, the share of NCD pro-
curement value to total procurement value was in range of 1.32% to 37%. Similarly, 
the annual per capita spending was in range of 0.1 to 103 Indian Rupees (INR). 
The procurement prices across all the states were lower than the international 
reference price. The retail market prices were between 45%-3600% higher than the 
state procurement prices, and were higher on average by 6 times of international 
reference price. The defined daily dose estimates were not uniform for all ATC. The 
most neglected category among all ATC’s was mental health, in the range of 0.020-
56.688 DDD per 1000. cOnclusiOns: - There is limited access to NCD medicines 
in public health system in selected Indian states.
PHP98
consTrucTIng A comorbIdITy Index AccordIng To Iso-resource 
consumPTIon
Sicras-Mainar A.1, Navarro-Artieda R.2
1Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 2Hospital Universitari Germans 
Trias i Pujol, Badalona, Spain
Objectives: To construct a comorbidity index according to iso-consumption of 
health resources and their associated costs in routine clinical practice. MethOds: 
We made a multicentre study through review of computerized medical records. 
The study population consisted of patients assigned to seven primary care centres, 
two acute care hospitals and one social health centre, allmanaged by Badalona 
ServeisAssistencials SA. The following variables were analysed: age (0-100 years), 
sex, comorbidity (chronic diagnoses) and direct health care costs. We estimated 
the resource use and gross health care costs attributed to all patients requiring 
health care in 2013. Subsequently, an expert panel identified the most-prevalent 
chronic diseases (ICD-9). Subgroups were established according to age and number 
of chronic comorbidities. The main variables and comorbidities associated with 
the costs were identified using a multivariate model. This allowed a total score to 
be developed for each patient. Statistical analysis: Spearman’s correlation coef-
ficient, multiple logistic models and linear regression were used. A value of p < 0.05 
was identified as significant. Results: We recruited 103,764 patients (86.5% of the 
total). Mean age was 43.1 (23.9) years and 52.4% were female. The mean unit cost 
was € 836.9 (2032). The gross cost was associated with age (r = 44.8) and comor-
bidity (r = 0.512). The final score was obtained from the logistic model. The score 
obtained showed a good correlation with age (r = 81.8), comorbidity (r = 0.939) 
and the cost of health care (r = 0.696). The index obtained explained 44.7% of the 
gross cost. The index was better adapted to the adjusted costs. We describe the 
disaggregated results and the results according to levels of comorbidity (healthy, 
low, medium, high). cOnclusiOns: The comorbidity index obtained was shown 
to be a simple potential predictor of the cost of care and may be applied in routine 
clinical practice.
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Objectives: The pace of innovation in health care has facilitated gains in life 
expectancy, but at a tremendous cost. Rational use of limited health care resources 
remains one of the greatest challenges in health care worldwide. This analysis 
sought to compare health care spending and health outcomes in countries with 
and without formal health technology assessment programs. MethOds: Data 
was collected on health care spending from 1990-2012 in European countries with 
and without HTA and compared to the United States, which eschews any formal 
evaluation of comparative or cost effectiveness. Measures of health outcomes were 
considered, including life expectancy and overall mortality. The impact of popula-
tion age, tobacco use and obesity rates on health outcomes were considered. Lastly, 
the number, content and methodology of HTA publications in countries with HTA 
were assessed. Results: The majority of HTA evaluations have focused on phar-
maceuticals. Countries with established HTA had lower spending on pharmaceu-
ticals, but not always lower overall health care spending, while maintaining or 
improving health outcomes relative to non-HTA countries. The United States had 
the highest rate and annual increase in rate in pharmaceutical spending as well as 
overall health care spending, with the worst health care outcomes in countries ana-
lyzed. cOnclusiOns: The incorporation of formal health technology assessment as 
part of overall health care decision making appears to assist in controlling the rise 
in health care spending, particularly drug spending. While better health outcomes 
in life expectancy and mortality were found in HTA versus non-HTA countries, 
correlation versus causality can only be considered at this point. Systematic use of 
HTA on both pharmaceutical and non-pharmaceutical interventions may help to 
control overall health care spending.
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Objectives: Health Transformation Program was started at year 2002 by Ministry of 
Health (MoH) in Turkey. Today, Turkey has a well established health system mostly 
dominated by government on health care provider and payer. The program allows 
the patient access to all drugs. There was an increasing trend for the pharmaceu-
tical consumption in years depending on the taken policies as other health care 
services. The aim of this study is to review an analysis for the new drug release 
prices for Turkey in the recent years. MethOds: The data was obtained from the 
last price list of each calender year published by MoH for the years between 2009-
2014. The year 2014 year data limited with the first quarter (Q1). The data classified 
in three groups which were; over 100 TL, over 1000 TL and over 10000 TL. All the 
result were based on ex-factory prices. A descriptive analysis was conducted on 
the price lists with the number of the products, maximum and average ex-factory 
prices. Results: The numbers of new released products over 100 TL were; 1, 7, 58, 
36 and 52 in the years 2009, 2010, 2011, 2012 and 2013, respectively. The numbers 
of new released products over 1000 TL were; 0, 1, 10, 11 and 13 in the years 2009, 
2010, 2011, 2012 and 2013, respectively. The highest ex-factory prices were 739 TL, 
1117 TL, 4066, 72 TL, 5781, 05 TL, 22791, 55 TLand 36577, 33 in the years 2009, 2010, 
2011, 2012 and 2013, respectively. The average ex-factory prices were 178, 98 TL, 329, 
28 TL, 214, 36 TL, 312, 93, 497, 44 TL and 612, 85 TL in the years 2009, 2010, 2011, 2012, 
2013 and 2014Q1 respectively. cOnclusiOns: It was shown that the number of 
high prices drugs, the highest price and the average price of the new drugs were 
increased year by year. Increased patient access may encoruage pharmaceutical 
companies to enter the Turkish market with their innovative drugs which have high 
price tag compared to regular drugs.
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Objectives: The 2008 global financial crisis hit Portugal strongly culminating 
in request financial assistance from European Union and International 
Monetary Fund on 17th May of 2011. In addition, Portuguese economy had already 
before 2008 a decreasing real growth rate of GDP, stagnant from early in the dec-
ade, and an increasing external deficit. Health care measures represented a key 
area within the assistance program. Specific targets were set for public spend-
ing in pharmaceuticals in order to align with EU average at 1.25 and 1.0 percent 
of GPD for 2012 and 2013, respectively. The aim of our study was to demonstrate 
that GDP targets was a political decision not supported by evidence, techni-
cally inaccurate, created a hurdle and equity asymmetries for patients access to 
medications, as well as jeopardized the future sustainability of Pharmaceutical 
sector. MethOds: We analyzed health, pharmaceuticals and medicines public 
spending EU benchmark in real terms, GDP ratio and per capita. We also revise 
the System of Health Accounts methodology and conceptual framework of 
International Classification of Health Accounts. OECD definitions, sources and 
methods were also studied. Results: Despite the efforts to improve the com-
parability across countries through common and better information framework 
of greater relevance for policy concerns, we observed that such approach is not 
recommended. For a more comprehensive understanding of health spending in 
relation to GDP ratio, it should be considered together with health spending per 
capita. Portugal comparisons are an OECD example for this rational. Importantly, 
OECD measures of pharmaceutical spending exclude in-patient (hospital) spend-
ing. In addition, pharmaceuticals definition is broader than prescription medicines 
only. cOnclusiOns: Important political decisions were taken assuming pharma-
ceuticals and prescription medicines as the same concept. Here, we demonstrate 
